FDA approved an update to the labeling for Zimmer Biomet’s Mobi-C® Cervical Disc to include 7-year clinical results. The updated data is consistent with previous findings at 60 months, that at 84 months of follow-up, Mobi-C is statistically non-inferior in overall study success for 1-level use and statistically superior in terms of overall study success for 2-level use.
Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis designed as a bone-sparing, cervical intervertebral disc replacement, and is the only FDA-approved disc for 1- and 2-level use.
The seven-year, prospective, randomized clinical trial compared cTDR with Mobi-C to ACDF and followed ~600 patients. The study showed that cTDR with Mobi-C was associated with nominally lower pain scores, maintained range of motion and resulted in less adjacent level degeneration and adjacent level subsequent surgery, as well as a lower rate of secondary surgery compared to ACDF.
The study was published in the International Journal of Spine Surgery in March.
Source: Zimmer Biomet; ORTHOWORLD, Inc.
FDA approved an update to the labeling for Zimmer Biomet’s Mobi-C® Cervical Disc to include 7-year clinical results. The updated data is consistent with previous findings at 60 months, that at 84 months of follow-up, Mobi-C is statistically non-inferior in overall study success for 1-level use and statistically superior in terms of overall study...
FDA approved an update to the labeling for Zimmer Biomet’s Mobi-C® Cervical Disc to include 7-year clinical results. The updated data is consistent with previous findings at 60 months, that at 84 months of follow-up, Mobi-C is statistically non-inferior in overall study success for 1-level use and statistically superior in terms of overall study success for 2-level use.
Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis designed as a bone-sparing, cervical intervertebral disc replacement, and is the only FDA-approved disc for 1- and 2-level use.
The seven-year, prospective, randomized clinical trial compared cTDR with Mobi-C to ACDF and followed ~600 patients. The study showed that cTDR with Mobi-C was associated with nominally lower pain scores, maintained range of motion and resulted in less adjacent level degeneration and adjacent level subsequent surgery, as well as a lower rate of secondary surgery compared to ACDF.
The study was published in the International Journal of Spine Surgery in March.
Source: Zimmer Biomet; ORTHOWORLD, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.